Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.

Anavex President & CEO Christopher U. Missling, PhD, will be presenting preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19, 2017. May 17-19, 2017 | Turnberry Isle Miami Hotel  | Aventura, Florida Antiepileptic Drug Trials XIV Conference | May 2017 Friday, May 19, 2017 3:10pm ET ANAVEX 2-73, A…